Imifoplatin clinical trials
Also written PT-112.
How each study uses imifoplatin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imifoplatin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Promontory Therapeutics Inc. (3) · SciClone Pharmaceuticals (2) · National Cancer Institute (NCI) (1) · SciClone Pharmaceuticals International (Cayman) Development Limited (1)
Studies
Open first, then newest update. How each study uses imifoplatin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- PT-112 in Subjects With Thymoma and Thymic CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05104736Written as PT-112
- A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsActive, not recruitingPhase 2Promontory Therapeutics Inc.NCT02266745Written as PT-112 Injection
- A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With AvelumabCompletedPhase 1/2Promontory Therapeutics Inc.NCT03409458Written as PT-112
- PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid TumorsStatus unknownPhase 1/2SciClone PharmaceuticalsNCT05357196Written as PT-112
- A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Promontory Therapeutics Inc.NCT03288480Written as PT-112
- An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation StudyStatus unknownPhase 1/2SciClone Pharmaceuticals International (Cayman) Development LimitedNCT02884479Written as PT-112
- An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular CarcinomaStatus unknownPhase 1/2SciClone PharmaceuticalsNCT03439761Written as PT-112 Injection
Codes
What other systems call imifoplatin · ClinicalTrials.gg INT016524
- UNII (FDA) F5I3T42BXCIMIFOPLATINOne source FDA
- NCI Thesaurus C121375ImifoplatinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F5I3T42BXC | IMIFOPLATIN | One source FDA |
| NCI Thesaurus | C121375 | Imifoplatin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.